Swiss National Bank increased its stake in shares of Omnicell Inc. (NASDAQ:OMCL) by 1.5% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 59,800 shares of the company’s stock after buying an additional 900 shares during the period. Swiss National Bank owned approximately 0.17% of Omnicell worth $2,047,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in OMCL. Glenmede Trust Co. NA boosted its position in shares of Omnicell by 31.5% in the first quarter. Glenmede Trust Co. NA now owns 1,011,363 shares of the company’s stock worth $28,185,000 after buying an additional 242,052 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Omnicell by 0.8% in the first quarter. Royal Bank of Canada now owns 685,223 shares of the company’s stock worth $19,097,000 after buying an additional 5,387 shares in the last quarter. Fisher Asset Management LLC boosted its position in shares of Omnicell by 1.0% in the second quarter. Fisher Asset Management LLC now owns 536,152 shares of the company’s stock worth $19,452,000 after buying an additional 5,152 shares in the last quarter. Henderson Group PLC boosted its position in shares of Omnicell by 57.6% in the second quarter. Henderson Group PLC now owns 399,565 shares of the company’s stock worth $13,677,000 after buying an additional 145,997 shares in the last quarter. Finally, Teachers Advisors Inc. boosted its position in shares of Omnicell by 9.2% in the first quarter. Teachers Advisors Inc. now owns 375,920 shares of the company’s stock worth $10,477,000 after buying an additional 31,762 shares in the last quarter. Hedge funds and other institutional investors own 95.26% of the company’s stock.

Omnicell Inc. (NASDAQ:OMCL) traded up 0.98% during midday trading on Tuesday, hitting $38.05. 90,958 shares of the stock traded hands. Omnicell Inc. has a 12-month low of $25.06 and a 12-month high of $40.50. The firm’s 50 day moving average is $37.86 and its 200-day moving average is $33.01. The stock has a market capitalization of $1.38 billion, a PE ratio of 96.57 and a beta of 0.69.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, July 28th. The company reported $0.38 EPS for the quarter, topping the Zacks’ consensus estimate of $0.32 by $0.06. Omnicell had a net margin of 2.36% and a return on equity of 10.41%. The firm earned $175.60 million during the quarter, compared to analysts’ expectations of $170.89 million. During the same period in the previous year, the business posted $0.28 earnings per share. The company’s revenue for the quarter was up 55.7% compared to the same quarter last year. On average, analysts anticipate that Omnicell Inc. will post $1.58 EPS for the current fiscal year.

A number of brokerages have recently issued reports on OMCL. Sidoti cut shares of Omnicell from a “buy” rating to a “neutral” rating and set a $43.00 price objective for the company. in a research note on Thursday, September 8th. Zacks Investment Research upgraded shares of Omnicell from a “hold” rating to a “strong-buy” rating and set a $41.00 price objective for the company in a research note on Monday, July 11th. FBR & Co increased their price objective on shares of Omnicell from $40.00 to $41.00 and gave the company an “outperform” rating in a research note on Friday, July 29th. Finally, Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $46.00 price objective on shares of Omnicell in a research note on Tuesday, September 13th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $38.13.

In other Omnicell news, VP Jorge R. Taborga sold 10,023 shares of Omnicell stock in a transaction on Friday, July 29th. The shares were sold at an average price of $40.00, for a total transaction of $400,920.00. Following the completion of the transaction, the vice president now directly owns 49,073 shares of the company’s stock, valued at $1,962,920. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gary S. Petersmeyer sold 2,400 shares of Omnicell stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $39.39, for a total transaction of $94,536.00. Following the transaction, the director now directly owns 17,987 shares of the company’s stock, valued at $708,507.93. The disclosure for this sale can be found here. Company insiders own 3.75% of the company’s stock.

About Omnicell

Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.

5 Day Chart for NASDAQ:OMCL

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell Inc. (NASDAQ:OMCL).

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.